Lead Sponsor

Merck Sharp & Dohme LLC

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Subjects must have a diagnosis of moderate to severe plaque-type psoriasis and have had participated in Study P05319.
•Subjects must have demonstrated an adequate but suboptimal response to infliximab in Study P05319
•Subjects must be at least 18 years old
•Subjects must be candidates for phototherapy or systemic treatment for psoriasis.
•Subjects must not be pregnant and must meet contraceptive requirements
•Subjects must meet tuberculosis screening criteria
•Subjects must meet laboratory and medical history screening requirements

•Subjects for whom infliximab or methotrexate is contraindicated or not recommended.
•Subjects already using certain investigational, biological, or immunosuppressive drugs
•Subjects with certain comorbid conditions
•Subjects who currently have or have a history of certain infections
•Subjects who have recently received live virus or bacterial vaccinations
•Subjects who are in a situation or have any condition that, in the opinion of the investigator, may interfere with optimal participation in the study.

Related studies

NCT07474792 · Plaque Psoriasis

NCT06857942 · Psoriasis, Overweight or Obesity

NCT06979453 · Plaque Psoriasis

NCT07449234 · Psoriasis

NCT07471048 · Psoriasis

Dose Optimization of Infliximab in Moderate to Severe Plaque Psoriasis (Study P05315)